Europe Renal Denervation Devices Market - Growth, Trends, and Forecast (2022 - 2027)
Europe Renal Denervation Devices Market is expected to register a CAGR of 5% during the forecast period. The major factors responsible for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure. High blood pressure is called hypertension. The prevalence of hypertension has been observing a significant rise, over the past few years. Generally, blood pressure rises and falls throughout the day, but it can damage one’s heart and result in health problems if hypertension stays high for a long time. The prevalence of hypertension in Germany (55%) is twice as high as in Canada and the United States. According to an article of Samuel Muli published in 2020, the prevalence of hypertension (≥140/90 mmHg) was 73.8%, representing 74.8% in men, and 73.5% in women per 1000 population. The heavy burden of hypertension is expected to drive the market growth during the forecast period.
Moreover, There are significantly more renal denervation devices, which have received CE approval, in the region. As per the clinicaltrials.gov, Abbott Medical Devices completed the observational study of the EnligHTN renal denervation system in Europe, in February 2019.Key Market TrendsThe Ultrasound-based Segment is Expected to be the Fastest Growing Segment
The ultrasound-based renal denervation devices are a minimally invasive procedure, using ultrasound to ablate nerves in the wall of the renal arteries, and it disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure. Additionally, according to the first randomized trial to compare the techniques (RADIOSOUND-HTN trial), the ultrasound-based renal denervation (RDN) approach has led to greater reductions in blood pressure than radiofrequency ablation in patients, with resistant hypertension. The rising prevalence of hypertension is expected to boost the overall growth of the market studied.
Recor Medical's Paradise Renal Denervation System is one of the commonly used ultrasound device. It is approved in European markets and under trials for FDA approval. According to the European Society of Cardiology’s comparative study of trials, Radiance-HTN Solo (ultrasound-based device- Paradise) showed more efficacy than the radiofrequency based SPYRAL HTN-OFF MED trial device. The device Paradise reduced -6.3 mmHg in daytime ambulatory BP and of -6.5 mmHg in office systolic BP compared to the sham group. The high efficacy of ultrasound-based devices proven in the trials is expected to increase the importance of these devices and revive them.Competitive Landscape
The Europe Renal Denervation Devices Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Medtronic PLC, Boston Scientific Corporation , St. Jude Medical Inc., ReCor Medical Inc.,Ablative Solutions Inc., Mercator MedSystems, Terumo Corporation, Symple SurgicalAdditional Benefits:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook